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Christopher M. O’Connor, MD; Robert M. Califf, MD; Paul W. Armstrong, MD; Justin A. Ezekowitz, MBBCh, MSc
Background-—Patients with acute heart failure (AHF) frequently have atrial ﬁbrillation (AF), but how this affects patient-reported
outcomes has not been well characterized.
Methods and Results-—We examined dyspnea improvement and clinical outcomes in 7007 patients in the Acute Study of Clinical
Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial. At baseline, 2677 (38.2%) patients had current or a
history of AF and 4330 (61.8%) did not. Patients with a history of AF were older than those without (72 vs. 63 years) and had more
comorbidities and a higher median left ventricular ejection fraction (31% vs. 27%, P<0.001). Compared to those without AF,
patients with AF had a similar mean ventricular rate on admission (81 vs. 83 beats per minute [bpm]; P=0.138) but a lower rate at
discharge (75 vs. 78 bpm; P<0.001). There was no difference in dyspnea improvement between patients with and without AF at
6 hours (P=0.087), but patients with AF had less dyspnea improvement at 24 hours (P<0.001). Compared to patients without AF,
patients with AF had a higher 30-day all-cause mortality rate (4.7% vs. 3.3%; P=0.005), a higher 30-day HF rehospitalisation rate
(7.2% vs. 5.3%; P=0.001), and a higher coprimary composite outcome of 30-day death or readmission (11.6% vs. 8.6%; P<0.001).
This difference persisted after adjustment for prognostic variables (adjusted odds ratio=1.19; (95% conﬁdence interval, 1.02 to
1.38; P=0.029).
Conclusions-—Among patients admitted to the hospital with AHF, current or a history of AF is associated with less dyspnea
improvement and higher morbidity and mortality at 30-days, compared to those not in AF.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00475852. ( J Am Heart Assoc. 2015;4:
e002092 doi: 10.1161/JAHA.115.002092)
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A trial ﬁbrillation (AF) is the most common chronic cardiacarrhythmia associated with acute or chronic heart failure
(HF) with a prevalence of 30% to 45%.1–6 In the setting of
acute heart failure (AHF), AF is associated with signiﬁcant
morbidity and an increased mortality rate.7,8 AF is also
associated with worsening in-hospital outcomes among
patients hospitalized for AHF9; however, its association with
dyspnea relief is unknown, and this has not been well
characterized in a contemporary, large international trial.
Despite the importance of heart rate as a predictor of
clinical outcomes for patients with sinus rhythm,10 limited
information about the relationship of heart rate (or the change
in heart rate) to postdischarge outcomes is known in patients
with AF and AHF.11 Furthermore, quality of care, such as
anticoagulation for patients with AF, is important given that it
is linked to clinical outcomes and subject to geographical
variation, patient characteristics, and system-related
features.7,12
Accordingly, we evaluated the baseline clinical character-
istics, dyspnea improvement, and readmission and death in
patients with and without AF in the ASCEND-HF trial. We also
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explored adequacy of ventricular rate control and use of
anticoagulation as measures of quality of care in patients with
AF and AHF.
Methods
Study Design
The study design and the primary results of the ASCEND-HF
trial have been published.5,13 In brief, the trial was conducted,
with ethical approval, beginning May 18, 2007 through August
2010 at 398 centers globally. All patients gave written
informed consent. Patients were included in ASCEND-HF if
they were hospitalized for ADHF occurring within 24 hours
before they received their ﬁrst intravenous treatment for HF
or if they had received a diagnosis of ADHF <48 hours after
hospitalization for another cause and underwent randomiza-
tion <24 hours after intravenous treatment for HF. Other
criteria for inclusion included: dyspnea at rest or with minimal
activity; 1 or more accompanying signs (respiratory rate
≥20 breaths per minute or pulmonary congestion or edema
with rales one third of the way or more up the lung ﬁelds); and
1 or more additional measures of HF (evidence of congestion
or edema on chest radiography, a B-type natriuretic peptide
[BNP] level ≥400 pg/mL or an N-terminal pro-BNP [NT-pro-
BNP] level ≥1000 pg/mL, pulmonary capillary wedge pres-
sure >20 mm Hg, or left ventricular (LV) ejection fraction
[LVEF] <40% in the previous 12 months). Complete eligibility
and exclusion criteria are described elsewhere.13,14 Patient
with or without AF were allowed into the study, and there was
no inclusion or exclusion criteria related to heart rate. Given
that no treatment effect on mortality or rehospitalization with
the study drug nesiritide was demonstrated, the treatment
arms were pooled in this analysis. Patients who did not
receive study drug were excluded from this analysis (n=134;
1.9%).
Demographic, clinical, laboratory, and diagnostic data were
collected at randomization. In addition to this, further blood
pressure (BP), laboratory, and medication data, as well as
subsequent diagnostic testing, were collected up to, and
including, hospital discharge. Patients were followed by a
clinical visit at 30 and 180 days after discharge.
AF Deﬁnition
Patients were classiﬁed as having AF if it was identiﬁed on the
case report form in the baseline medical history section (ie, a
history of or current AF). Where appropriate and possible, this
has been referred to as “patients with AF.” No core lab
reading of electrocardiogram (ECG) was performed, but
patients in ASCEND-HF were recommended to have appro-
priate standard of care, which includes an ECG when
presenting with AHF.15 A total of 5378 (77%) patients had
information from a baseline ECG entered on the case report
form; however, this did not include reporting of sinus rhythm
or atrial ﬁbrillation from the ECG as a speciﬁc variable.
Clinical Outcomes
For this analysis, we examined the ASCEND-HF coprimary
endpoint of 6- and 24-hour dyspnea relief (measured using a
7-point Likert scale) and the coprimary composite of 30-day
all-cause mortality or HF rehospitalisation, its individual
components and 180-day all-cause mortality.
Quality-of-Care Outcome
We measured adherence rates to quality-of-care measures
(QCM) based on the Class I American College of Cardiology/
American Heart Association (ACC/AHA) recommendations for
care of patients with HF,16 as used in the Get With The
Guidelines (GWTG)-HF program.17 Speciﬁcally, we examined
the use of oral anticoagulation for patients with atrial
ﬁbrillation at hospital discharge, barring documented con-
traindications, intolerances or speciﬁc reasons for nonuse, or
documented plan for initiation at a later date. The use of
antithrombotic medication (ie, an antiplatelet or an anticoag-
ulant) was also evaluated according to the CHADS2 score.
18
Because patients in ASCEND-HF were admitted with AHF, all
had a CHADS2 score ≥1. We also examined control of the
ventricular (“heart”) rate in patients with AF over the course of
their admission.
Statistical Analysis
Baseline patient characteristics and clinical outcomes are
reported according to whether or not patients had a history of
AF at baseline. Data for continuous variables are presented as
medians with 25th and 75th percentiles, and categorical
variables are presented as frequencies and percentages.
Wilcoxon’s rank-sum tests were used to measure differences
for continuous variables, and the chi-square or Fisher’s exact
tests were used for categorical variables. Statistical signiﬁ-
cance was determined at the 2-sided a=0.05 level.
Multivariable models, which were previously developed in
the ASCEND-HF trial, were used to adjust the associations of
AF with 30-day outcomes (all-cause death and HF rehospital-
ization), and with 31- to 180-day outcomes (all-cause death).
These models included the following characteristics at the
time of randomization for 30-day outcomes: age; blood urea
nitrogen (BUN); serum sodium; dyspnea severity; and systolic
blood pressure (SBP). Resultant odds ratios (ORs) are
presented with 95% conﬁdence intervals (CIs) comparing
patients with AF to patients without AF (reference group). The
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adjustment model for 31- to 180-day mortality included age,
weight, BUN, SBP, sodium, dyspnea severity, and elevated
jugular venous pressure; previous history of cerebrovascular
disease, chronic obstructive pulmonary disease (COPD)/
chronic respiratory disease; and HF rehospitalization 1 year
before admission. Resultant hazard ratios (HRs) are presented
with 95% CIs comparing patients with AF to patients without
AF (reference group). Clinically meaningful 2-way interactions
between age, dyspnea severity, and CHADS2 score and AF
status were also evaluated; none were signiﬁcant.
All tests were 2-sided with a 5% level of signiﬁcance. All
analyses were performed using SAS statistical analysis
software (version 9.2; SAS Institute Inc, Cary, NC).
Results
Baseline Characteristics
Of the 7007 patients in the ASCEND-HF trial, 2677 (38.2%)
had a history of AF at baseline and 4330 (61.8%) did not have
a history of AF at baseline. Patients with AF were older, more
likely to be white, have a higher BMI, and had more
comorbidities, including diabetes, coronary artery disease,
previous, and COPD (Tables 1 and 2). There was no difference
in gender or vital signs (heart rate, SBP, and respiratory rate)
between those with and without AF. Patients with AF had a
higher ejection fraction (31% vs. 27%; P<0.001) and lower
BNP level (945 vs. 1051 pg/mL; P=0.005), compared to
those without AF; NT-proBNP levels were not, however,
different (AF: 4496 pg/mL; no AF: 4238 pg/mL; P=0.406).
Heart rate at baseline was similar between groups (83 bpm
in patients without AF vs. 81 bpm with AF; P=0.138). Patents
with current or a history of AF had a lower heart rate at
24 hours (78 vs. 80 bpm; P=0.012) and at discharge (75 vs.
80 bpm; P<0.001; Figure 1).
Dyspnea Improvement, Hospital Course, and
Clinical Outcomes
There was no difference in dyspnea improvement between
patients with or without AF at 6 hours (P=0.087). However,
patients with AF had less improvement in dyspnea during the
ﬁrst 24 hours (P<0.001; Figure 2).
Patients with AF had a longer median in-hospital length of
stay (7 vs. 6 days; P<0.001). Compared to patients without
AF, patients with AF had a higher in-hospital all-cause
mortality rate (2.6% vs. 1.7%; P=0.015), a higher 30-day all-
cause mortality rate (4.7% vs. 3.3%; P=0.005), a higher 31- to
180-day mortality rate (11.1% vs. 8%; P<0.001), and a higher
180-day mortality rate (15.3% vs. 11.1%; P<0.001). Patients
with AF also had a higher 30-day HF rehospitalisation rate
(7.2% vs. 5.3%; P=0.001). Hence, more patients in the AF
group experienced the coprimary composite outcome of
death or readmission at 30 days than in the group without AF
(8.6% vs. 11.6%; P<0.001). This difference persisted after
adjustment for the predeﬁned prognostic variables (adjusted
OR=1.19; 95% CI, 1.02 to 1.38; adjusted P=0.029; Table 3).
However, after adjustment, neither the difference in 30-day
mortality (adjusted OR=1.20; 95% CI, 0.91 to 1.58), or in 31-
to 180-day mortality was signiﬁcant (adjusted HR, 1.15; 95%
CI, 0.93 to 1.43).
Quality-of-Care Outcomes
In patients with current or a history of AF, anticoagulation
rates according to CHADS2 score at discharge were 61.5%,
59.1%, 58.7%, and 57.5% for scores of 1, 2, 3 or 4, and ≥5,
respectively (trend, P=0.782; Table 2; Figure 3). Antiplatelet
use in patients with current or a history of AF according to
CHADS2 score was 36.1%, 51.6%, 58.3%, and 61.1% for
scores of 1, 2, 3 or 4, and ≥5 respectively (trend, P<0.001).
Patients with current or a history of AF had a higher use of
anticoagulants and a lower use of antiplatelet agents across
all CHADS2 scores (all comparisons, P<0.001). Patients
without AF had higher use of antiplatelet across all CHADS2
scores (all comparisons, P<0.001), but anticoagulants use
was only higher in CHADS2 (≥5). The percentage of patients
with current or a history of AF discharged on neither an
antiplatelet nor anticoagulant was 17.6%, 14.2%, 12.3%, and
11.1% for CHADS2 scores of 1, 2, 3 or 4, and ≥5 respectively.
The percentage of patients with or without AF discharged
on any antiplatelet/anticoagulant was 86.7% and 76.9%,
respectively.
Discussion
In this retrospective analysis of patients with AHF enrolled in
the ASCEND-HF study, patients with current or a history of AF
had a 19% higher rate of the coprimary endpoint at 30 days,
and a lower rate of dyspnea improvement at 24 hours.
Second, we found that patients with current or a history of AF
had a lower heart rate on admission as well as discharge,
when compared to patients without AF. Third, the overall
anticoagulation or antiplatelet therapy rate was lower than
expected given the evidence base for the use of these agents
in patients with AF and provides an opportunity for improve-
ment.
Dyspnea is a key symptom in acute cardiovascular disease
and has been the focus as a primary endpoint for AHF clinical
trials.4,5 Interestingly, patients with current or a history of AF
in the ASCEND-HF trial had a trend to less dyspnea
improvement by 24 hours, when compared to patients
without AF. This occurred on the background of greater
baseline dyspnea at rest than patients without AF, and with
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Table 1. Baseline Patient Characteristics
Total (N=7007)
HF Without AF
(n=4330)
HF With Current or a
History of AF (n=2677) P Value
Age, y 67.0 (56.0, 76.0) 63.0 (53.0, 73.0) 72.0 (63.0, 79.0) <0.001
Female, n (%) 2391 (34.1) 1479 (34.2) 912 (34.1) 0.9391
Race, n (%) <0.001
Asian 1747 (24.9) 1450 (33.5) 297 (11.1)
White 3916 (55.9) 1874 (43.3) 2042 (76.3)
Black or African American 1040 (14.8) 784 (18.1) 256 (9.6)
Other 303 (4.3) 222 (5.1) 81 (3.0)
Vital signs
Weight, kg 78.0 (64.1, 95.0) 75.3 (62.0, 92.0) 82.0 (69.0, 98.0) <0.001
Body mass index 27.5 (23.8, 32.6) 27.0 (23.2, 32.2) 28.3 (24.6, 33.1) <0.001
Heart rate, beats per minute 82 (72, 95) 83 (72, 94) 81 (70, 96) 0.138
Respiratory rate, breaths per minute 23 (21, 26) 24 (21, 26) 23 (21, 25) 0.023
Systolic BP, mm Hg 123 (110, 140) 124 (110, 140) 122 (110, 138) 0.012
Diastolic BP, mm Hg 74 (67, 83) 75.0 (68, 85) 73.0 (65, 81) <0.001
Presenting signs and symptoms, n (%)
Dyspnea at rest 4339 (61.9) 2628 (60.7) 1711 (63.9) 0.007
Dyspnea with minimal activity 2667 (38.1) 1702 (39.3) 965 (36.1)
Orthopnea 5388 (77.0) 3322 (76.8) 2066 (77.2) 0.749
Pulmonary congestion 6088 (86.9) 3768 (87.1) 2320 (86.7) 0.689
JVP elevated 3934 (56.2) 2446 (56.5) 1488 (55.6) 0.449
S3 1642 (23.4) 1227 (28.4) 415 (15.5) <0.001
Peripheral edema 5234 (74.7) 3077 (71.1) 2157 (80.6) <0.001
Medical history, n (%)
Diabetes 2987 (42.6) 1952 (45.1) 1035 (38.7) <0.001
Smoking 2493 (35.6) 1437 (33.2) 1056 (39.5) <0.001
Hyperlipidemia 2914 (41.6) 1650 (38.1) 1264 (47.2) <0.001
CAD 3523 (50.3) 2044 (47.2) 1479 (55.2) <0.001
Previous PCI 1143 (16.3) 707 (16.3) 436 (16.3) 0.981
Previous CABG 1278 (18.2) 689 (15.9) 589 (22.0) <0.001
ICD only 597 (8.5) 355 (8.2) 242 (9.0) 0.220
Pacemaker only 433 (6.2) 151 (3.5) 282 (10.5) <0.001
CRT-D 535 (7.6) 256 (5.9) 279 (10.4) <0.001
PVD 725 (10.3) 392 (9.0) 333 (12.4) <0.001
CVA 823 (11.8) 399 (9.2) 424 (15.8) <0.001
COPD/asthma 1150 (16.4) 591 (13.6) 559 (20.9) <0.001
Laboratory investigations
Sodium, mmol/L 139 (136, 141) 138 (136, 141) 139 (137, 142) <0.001
Creatinine, lmol/mL 108.0 (88.4, 140.6) 106.1 (88.4, 134.4) 114.9 (89.3, 141.4) <0.001
Blood urea nitrogen, mmol/L 9.1 (6.4, 13.9) 8.8 (6.1, 13.6) 9.6 (6.8, 14.5) <0.001
BNP, pg/mL 990 (543, 1867) 1040 (536, 1974) 945 (561, 1644) 0.018
Continued
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>60% of both groups (AF and not AF) having a moderate or
marked improvement in dyspnea. Whether or not therapies
targeted at the underlying pathophysiology of AF would
provide greater dyspnea relief than diuretics or vasodilators is
uncertain, as is the underlying mechanism of dyspnea for
many patients. Given that dyspnea is a patient-reported
Table 1. Continued
Total (N=7007)
HF Without AF
(n=4330)
HF With Current or a
History of AF (n=2677) P Value
NT-proBNP, pg/mL 4312 (2140, 9048) 4238 (2087, 9266) 4496 (2369, 8842) 0.406
Troponin I, ng/mL 0.05 (0.03, 0.10) 0.06 (0.03, 0.11) 0.05 (0.03, 0.10) 0.003
Troponin T, ng/mL 0.02 (0.01, 0.04) 0.02 (0.01, 0.05) 0.02 (0.01, 0.04) 0.131
Ejection fraction, % 30.0 (20.0, 37.0) 27.0 (20.0, 35.0) 31.0 (24.0, 43.0) <0.001
Continuous variables are reported as median with 25th and 75th percentiles. AF indicates atrial ﬁbrillation; BNP, B-type natriuretic peptide; BP, blood pressure; CABG, coronary artery
bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRT-D, cardiac resynchronization–deﬁbrillator; CVA, cerebrovascular disease; HF, heart failure;
ICD, implantable cardioverter-deﬁbrillator; JVP, jugular venous pulse; NT-proBNP, N-terminal pro-BNP; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; S3, third
heart sound.
Table 2. Baseline and Discharge Medications
Total (N=7007)
HF Without
AF (n=4330)
HF With Current or a
History of AF (n=2677) P Value
Baseline medications
ACE/ARB inhibitors, n (%) 4256 (60.7) 2582 (59.6) 1674 (62.5) 0.016
Beta-blockers, n (%) 4074 (58.1) 2335 (53.9) 1739 (65.0) <0.001
MRA, n (%) 1950 (27.8) 1175 (27.1) 775 (29.0) 0.100
CCB, n (%) 901 (12.9) 505 (11.7) 396 (14.8) <0.001
Digoxin, n (%) 562 (8.0) 279 (6.4) 283 (10.6) <0.001
Antiarrhythmic agents, n (%) 819 (11.7) 291 (6.7) 528 (19.7) <0.001
Clopidogrel, n (%) 1123 (16.0) 851 (19.7) 272 (10.2) <0.001
Aspirin, n (%) 3435 (49.0) 2203 (50.9) 1232 (46.0) <0.001
Any antiplatelet agent, n (%) 3743 (53.4) 2436 (56.3) 1307 (48.8) <0.001
Anticoagulation agents, n (%) 1687 (24.1) 392 (9.0) 1295 (48.4) <0.001
No anticoagulant or antiplatelet agent, n (%) 2270 (32.4) 1679 (38.8) 591 (22.1) <0.001
Discharge medications
ACE/ARB inhibitors, n (%) 5210 (74.3) 3285 (75.9) 1925 (71.9) <0.001
Beta-blockers, n (%) 5102 (72.8) 3127 (72.2) 1975 (73.8) 0.154
MRA, n (%) 3238 (46.2) 2021 (46.7) 1217 (45.5) 0.322
CCB, n (%) 826 (11.8) 507 (11.7) 319 (11.9) 0.794
Digoxin, n (%) 2462 (35.1) 1336 (30.9) 1126 (42.1) <0.001
Antiarrhythmic agents, n (%) 967 (13.8) 396 (9.2) 571 (21.3) <0.001
Clopidogrel, n (%) 1317 (18.8) 1045 (24.1) 272 (10.2) <0.001
Aspirin, n (%) 4219 (60.2) 2833 (65.4) 1386 (51.8) <0.001
Any antiplatelet agent, n (%) 4540 (64.8) 3087 (71.3) 1453 (54.3) <0.001
Anticoagulation agents, n (%) 2067 (29.5) 488 (11.3) 1579 (59.0) <0.001
No anticoagulant or antiplatelet agent, n (%) 1354 (19.3) 999 (23.1) 355 (13.3) <0.001
Either of antiplatelet or anticoagulant, n (%) 5653 (80.7) 3331 (76.9) 2322 (86.7) <0.001
Antiarrhythmic agents included amiodarone, dronedarone, or sotalol. ACE/ARB indicates angiotensin-converting enzyme/angitensin receptor blocker; AF, atrial ﬁbrillation; CCB, calcium-
channel blocker; HF, heart failure; MRA, mineralocorticoid antagonist.
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symptom, as opposed to an objective measure, such as peak
expiratory ﬂow rate,19 it remains uncertain whether other
patient features, other than heart rate, may be feeding into
their perception of breathlessness.
Although there was no difference in heart rate at
presentation between patients with or without AF, heart rate
was signiﬁcantly lower at 6 and 24 hours and at discharge in
patients with AF and less dyspnea relief at 24 hours for
patients with current or a history of AF. There are likely
multiple plausible explanations for this ﬁnding, including
choices for therapy, aggressiveness of heart rate as a clinical
target for therapy, underlying differences in patient charac-
teristics, activation of the sympathetic nervous system, and
features related to the conduct of a clinical trial. Patients with
current or a history of AF in ASCEND-HF had high rates of
digoxin use as well as antiarrhythmic medications, which may
reﬂect local variation in practice in a global trial, or clinicians
using these medications to actively lower the heart rate or
improve symptoms (noting the rate of beta-blocker use was
similar in patients with or without a current or a history of AF).
Additionally, we noted that BNP levels (but not NT-proBNP
levels) were lower in patients with AF, in contradistinction to
other studies. This may be explained, in part, by trial entry
criteria, which allowed for patients with an elevated BNP to be
enrolled without distinction of AF, as is now done in other
trials.4 This may be further compounded by an older age,
worse renal function, and higher rates of coronary artery
disease burden, which may be related and increase levels of
NT-proBNP.20,21
In this study, there was greater usage of anticoagulation
therapy among patients with current or a history of AF than
those without AF across all CHADS2 scores; however, there is
still undertreatment with anticoagulation. In a previous study
from ASCEND-HF, signiﬁcant global variation was noted when
anticoagulation for patients with current or a history of AF
was assessed by quality performance metrics, with only 33%
of Asia-Paciﬁc and 76% of Western Europe meeting the quality
performance metric.12 Whether this ﬁnding impacts longer-
term clinical outcomes is not elaborated in the current study;
Figure 2. Dyspnea improvement comparing patients with and
without AF. AF indicates atrial ﬁbrillation.
Figure 1. HR at different time points comparing patients with and
without AF. AF indicates atrial ﬁbrillation; HF, heart failure; HR,
heart rate.
Table 3. Clinical Event Rates of Patients With or Without AF
Total
(N=7007)
Without AF
(n=4330)
With Current or a
History of AF
(n=2677) P Value
Unadjusted
Association* P Value
Adjusted
Association*
Adjusted
P Value
30-day all-cause
mortality, n (%)
267 (3.8) 143 (3.3) 124 (4.6) 0.005 1.41 (1.10 to 1.81) 0.006 1.20 (0.91 to 1.58) 0.193
30-day HF-related
rehospitalization, n (%)
412 (6.0) 223 (5.3) 189 (7.2) 0.001 1.40 (1.14 to 1.70) 0.001 1.46 (1.17 to 1.82) 0.001
30-day mortality or HF-related
rehospitalization, n (%)
666 (9.7) 362 (8.6) 304 (11.6) <0.001 1.46 (1.28 to 1.67) <0.001 1.19 (1.02 to 1.38) 0.029
31- to 180-day all-cause
mortality, n (%)
609 (9.2) 329 (8.0) 280 (11.1) <0.001 1.36 (1.15 to 1.61) <0.001 1.15 (0.93 to 1.43) 0.194
AF indicates atrial ﬁbrillation; HF, heart failure.
*For 30-day outcomes, associations are presented as an odds ratio (95% conﬁdence interval). For 31- to 180-day mortality, hazard ratios (95% conﬁdence interval) are reported. The
reference group is patients without atrial ﬁbrillation. Adjusted for age, systolic blood pressure, blood urea nitrogen, sodium, and dyspnea severity.
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however, other studies of patients with AF and concomitant
HF or LV dysfunction have identiﬁed this as a risk factor for
stroke (and thus a target for anticoagulation).18,22 Though
there are geographical differences in the HF or AF guidelines
during the years of conduct of the ASCEND-HF trial, in
patients with a CHADS2 score ≥2, guidelines universally
recommend oral anticoagulation with or without concomitant
antiplatelet agents. Hospitalization provides an ideal time for
patients and clinicians to assess risks and beneﬁts of choices
for oral anticoagulation or antiplatelet strategy.
Conclusion
We found that patients with current or a history of AF differed
from those not in AF in their age, LVEF, comorbidity burden,
and other clinical features. Patients with current or a history
of AF had greater heart rate reduction by the day of discharge,
but less dyspnea relief and higher rates of readmission and
mortality. Finally, we also identiﬁed that many patients with
current or a history of AF do not receive appropriate stroke
prevention strategies despite the opportunity while in the
hospital to assess the risks and beneﬁts of oral anticoagu-
lants or antiplatelet agents.
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